Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirasol Whole Blood Pathogen Reduction for TTIs
NCT03737669Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2019
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Cumulative incidence of at least one (1) pre-defined TTI at 10 weeks. Started Nov 2019; status: completed.
Beyond the preview
Go deeper on NCT03737669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737669.